Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib-Reference-Cited by-同舟云学术

Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

Published:2017-11 Issue:11 Volume:17 Page:728-733
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Pagnano Katia Borgia Barbosa,Miranda Eliana Cristina,Delamain Márcia Torresan,Duarte Gislaine Oliveira,de Paula Erich Vinicius,Lorand-Metze Irene,de Souza Carmino Antonio

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference19 articles.

1. The molecular biology of chronic myeloid leukaemia;Melo;Leukemia,1996

2. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype;Melo;Blood,1996

3. Current developments in molecular monitoring in chronic myeloid leukemia;Marum;Ther Adv Hematol,2016

4. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors;Jain;Blood,2016

5. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib;Hanfstein;Haematologica,2014

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival;Genes;2024-04-28

2. Frequencies of BCR::ABL1 Transcripts in Patients with Chronic Myeloid Leukemia: A Meta-Analysis;Genes;2024-02-12

3. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

4. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response;Journal of Clinical Medicine;2024-01-29

5. Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights;Cells;2023-06-23